Cargando…
5-Hydroxymethylcytosine discriminates between parathyroid adenoma and carcinoma
BACKGROUND: Primary hyperparathyroidism is characterized by enlarged parathyroid glands due to an adenoma (80–85 %) or multiglandular disease (~15 %) causing hypersecretion of parathyroid hormone (PTH) and generally hypercalcemia. Parathyroid cancer is rare (<1–5 %). The epigenetic mark 5-hydroxy...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4789293/ https://www.ncbi.nlm.nih.gov/pubmed/26973719 http://dx.doi.org/10.1186/s13148-016-0197-2 |
_version_ | 1782420829895655424 |
---|---|
author | Barazeghi, Elham Gill, Anthony J. Sidhu, Stan Norlén, Olov Dina, Roberto Palazzo, F. Fausto Hellman, Per Stålberg, Peter Westin, Gunnar |
author_facet | Barazeghi, Elham Gill, Anthony J. Sidhu, Stan Norlén, Olov Dina, Roberto Palazzo, F. Fausto Hellman, Per Stålberg, Peter Westin, Gunnar |
author_sort | Barazeghi, Elham |
collection | PubMed |
description | BACKGROUND: Primary hyperparathyroidism is characterized by enlarged parathyroid glands due to an adenoma (80–85 %) or multiglandular disease (~15 %) causing hypersecretion of parathyroid hormone (PTH) and generally hypercalcemia. Parathyroid cancer is rare (<1–5 %). The epigenetic mark 5-hydroxymethylcytosine (5hmC) is reduced in various cancers, and this may involve reduced expression of the ten-eleven translocation 1 (TET1) enzyme. Here, we have performed novel experiments to determine the 5hmC level and TET1 protein expression in 43 parathyroid adenomas (PAs) and 17 parathyroid carcinomas (PCs) from patients who had local invasion or metastases and to address a potential growth regulatory role of TET1. RESULTS: The global 5hmC level was determined by a semi-quantitative DNA immune-dot blot assay in a smaller number of tumors. The global 5hmC level was reduced in nine PCs and 15 PAs compared to four normal tissue samples (p < 0.05), and it was most severely reduced in the PCs. By immunohistochemistry, all 17 PCs stained negatively for 5hmC and TET1 showed negative or variably heterogeneous staining for the majority. All 43 PAs displayed positive 5hmC staining, and a similar aberrant staining pattern of 5hmC and TET1 was seen in about half of the PAs. Western blotting analysis of two PCs and nine PAs showed variable TET1 protein expression levels. A significantly higher tumor weight was associated to PAs displaying a more severe aberrant staining pattern of 5hmC and TET1. Overexpression of TET1 in a colony forming assay inhibited parathyroid tumor cell growth. CONCLUSIONS: 5hmC can discriminate between PAs and PCs. Whether 5hmC represents a novel marker for malignancy warrants further analysis in additional parathyroid tumor cohorts. The results support a growth regulatory role of TET1 in parathyroid tissue. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13148-016-0197-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4789293 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-47892932016-03-14 5-Hydroxymethylcytosine discriminates between parathyroid adenoma and carcinoma Barazeghi, Elham Gill, Anthony J. Sidhu, Stan Norlén, Olov Dina, Roberto Palazzo, F. Fausto Hellman, Per Stålberg, Peter Westin, Gunnar Clin Epigenetics Research BACKGROUND: Primary hyperparathyroidism is characterized by enlarged parathyroid glands due to an adenoma (80–85 %) or multiglandular disease (~15 %) causing hypersecretion of parathyroid hormone (PTH) and generally hypercalcemia. Parathyroid cancer is rare (<1–5 %). The epigenetic mark 5-hydroxymethylcytosine (5hmC) is reduced in various cancers, and this may involve reduced expression of the ten-eleven translocation 1 (TET1) enzyme. Here, we have performed novel experiments to determine the 5hmC level and TET1 protein expression in 43 parathyroid adenomas (PAs) and 17 parathyroid carcinomas (PCs) from patients who had local invasion or metastases and to address a potential growth regulatory role of TET1. RESULTS: The global 5hmC level was determined by a semi-quantitative DNA immune-dot blot assay in a smaller number of tumors. The global 5hmC level was reduced in nine PCs and 15 PAs compared to four normal tissue samples (p < 0.05), and it was most severely reduced in the PCs. By immunohistochemistry, all 17 PCs stained negatively for 5hmC and TET1 showed negative or variably heterogeneous staining for the majority. All 43 PAs displayed positive 5hmC staining, and a similar aberrant staining pattern of 5hmC and TET1 was seen in about half of the PAs. Western blotting analysis of two PCs and nine PAs showed variable TET1 protein expression levels. A significantly higher tumor weight was associated to PAs displaying a more severe aberrant staining pattern of 5hmC and TET1. Overexpression of TET1 in a colony forming assay inhibited parathyroid tumor cell growth. CONCLUSIONS: 5hmC can discriminate between PAs and PCs. Whether 5hmC represents a novel marker for malignancy warrants further analysis in additional parathyroid tumor cohorts. The results support a growth regulatory role of TET1 in parathyroid tissue. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13148-016-0197-2) contains supplementary material, which is available to authorized users. BioMed Central 2016-03-12 /pmc/articles/PMC4789293/ /pubmed/26973719 http://dx.doi.org/10.1186/s13148-016-0197-2 Text en © Barazeghi et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Barazeghi, Elham Gill, Anthony J. Sidhu, Stan Norlén, Olov Dina, Roberto Palazzo, F. Fausto Hellman, Per Stålberg, Peter Westin, Gunnar 5-Hydroxymethylcytosine discriminates between parathyroid adenoma and carcinoma |
title | 5-Hydroxymethylcytosine discriminates between parathyroid adenoma and carcinoma |
title_full | 5-Hydroxymethylcytosine discriminates between parathyroid adenoma and carcinoma |
title_fullStr | 5-Hydroxymethylcytosine discriminates between parathyroid adenoma and carcinoma |
title_full_unstemmed | 5-Hydroxymethylcytosine discriminates between parathyroid adenoma and carcinoma |
title_short | 5-Hydroxymethylcytosine discriminates between parathyroid adenoma and carcinoma |
title_sort | 5-hydroxymethylcytosine discriminates between parathyroid adenoma and carcinoma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4789293/ https://www.ncbi.nlm.nih.gov/pubmed/26973719 http://dx.doi.org/10.1186/s13148-016-0197-2 |
work_keys_str_mv | AT barazeghielham 5hydroxymethylcytosinediscriminatesbetweenparathyroidadenomaandcarcinoma AT gillanthonyj 5hydroxymethylcytosinediscriminatesbetweenparathyroidadenomaandcarcinoma AT sidhustan 5hydroxymethylcytosinediscriminatesbetweenparathyroidadenomaandcarcinoma AT norlenolov 5hydroxymethylcytosinediscriminatesbetweenparathyroidadenomaandcarcinoma AT dinaroberto 5hydroxymethylcytosinediscriminatesbetweenparathyroidadenomaandcarcinoma AT palazzoffausto 5hydroxymethylcytosinediscriminatesbetweenparathyroidadenomaandcarcinoma AT hellmanper 5hydroxymethylcytosinediscriminatesbetweenparathyroidadenomaandcarcinoma AT stalbergpeter 5hydroxymethylcytosinediscriminatesbetweenparathyroidadenomaandcarcinoma AT westingunnar 5hydroxymethylcytosinediscriminatesbetweenparathyroidadenomaandcarcinoma |